Biotech Values

[zipjet]

Wedbush probably expects MNTA to reverse the balance-sheet offset to the NOL’s and run the deferred-tax asset on the balance sheet through the income statement in one fell swoop, which will encourage the sell-side analysts to ignore this non-recurring gain and model EPS on a fully-taxed basis.

Given the tL any-day overhang, I would not do that.

ij